Recently Opened Study: Triple Negative Breast Cancer Program

The Weill Cornell Breast Center recently opened a new triple negative breast cancer program. The study is for women diagnosed with triple negative breast cancer. There is an urgent need to develop new, targeted treatments for triple negative breast cancer. Through our Program, we plan to integrate research, treatment and education to accelerate and identify new targets and strategies to treat and cure triple negative breast cancer.

For more information about the study, please call Margie for a consult appointment with Dr. Vahdat at (212)-821-0644 and contact Naomi for more information at (212)-821-0984 or

“From a patient perspective this study requires very little of participants.  I think that for post-treatment women like me the opportunity to participate so easily in cutting edge research at a world-class institution like WCMC is a great way to ‘pay it forward’ in appreciation to all those women whose participation in past clinical trials directly benefited us in terms of improvements in how breast cancer is treated. This is an exceedingly rare opportunity!”

– Triple Negative Breast Cancer Program participant

BSGI Molecular Breast Imaging Significantly Improves Breast Cancer Detection

Results from a multi-center patient registry, presented at a recent National Consortium of Breast Centers Annual Meeting, demonstrate that Breast-Specific Gamma Imaging (BSGI) also known as Molecular Breast Imaging (MBI) improves breast cancer detection when added to mammography and ultrasound in the breast clinic.

In this study, BSGI/MBI detected cancers in nearly 13% of patients who had negative or indeterminate mammograms and an unresolved diagnostic concern such as subtle changes in the mammogram, breast pain, a new breast lump, nipple discharge, etc. Another 4% of these patients had a high-risk lesion detected by BSGI/MBI. BSGI performed significantly better than ultrasound, detecting 92% of cancers compared to just 60% by ultrasound.

According to co-author Dr. Jean Weigert of Mandell and Blau MDs PC, New Britain, CT, “The primary advantage of ultrasound is that it does not use radiation, however, a negative ultrasound can still miss cancers. Our results demonstrate that in cases where mammography and ultrasound are negative or indeterminate, BSGI can still detect some cancers. The BSGI study does involve low doses of radiation, but the benefit of early cancer detection dwarfs the health risk from the radiation dose. In fact, there has never been a reported health impact from such low radiation doses and the benefit is evident in our data. Even according to the most conservative risk-models, the benefit outweighs the risk 680 to 1.”

Weill Cornell Medical Center offers BSGI/MBI.